Full name
"ELI LILLY POLSKA" SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
uses securityreCAPTCHA
"ELI LILLY POLSKA" SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
UL. ŻWIRKI I WIGURY 18A, 02-092 WARSZAWA
TAX ID5261012594
Rate company:
"ELI LILLY POLSKA" SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
TAX ID5261012594
KRS0000034645
Share capital10,023,734.00 zł
address
UL. ŻWIRKI I WIGURY 18A, 02-092 WARSZAWA
Categories
Main category
Is this your company?Update company information to get new customers, get notified of new reviews, and more!
Register Data
NIP
5261012594
REGON
010741154
KRS
0000034645
Legal form
limited liability company
Register Address
UL. ŻWIRKI I WIGURY 18A, 02-092 WARSZAWA
Date of registration in KRS
2001-08-08
Date of commencement of economic activity
2001-08-08
Act signature
RDF/631045/24/841
Pkd codes
46.46.Z - Wholesale of pharmaceutical goods
21.10.Z - Manufacture of basic pharmaceutical substances
21.20.Z - Manufacture of medicines and other pharmaceutical products
70.22.Z - Business and other management consultancy activities
72.11.Z - Research and experimental development on biotechnology
73.11.Z - Advertising agencies activities
73.20.Z - Market research and public opinion polling
82.30.Z - Organisation of conventions and trade shows
82.99.Z - Other business support service activities not elsewhere classified
85.59.B - Other out-of-school forms of education, not elsewhere classified
Payer VAT status
Active
Vat list bank account(s)
PL61 1600 1127 0003 0121 2282 2001 
PL77 1600 1127 0003 0121 2282 2198 PL91 1600 1127 0003 0121 2282 2140 Financial data
Net sales [PLN]
Gross profit / loss [PLN]
Automatically generated based on financial statements from KRS Registry
| 2021 | 2022 | 2023 | ||
|---|---|---|---|---|
M PLN | M PLN | M PLN | % | |
Gross profit (loss)  | 5,4 | 10,8 | 15,6 | 43,8 |
EBITDA | 6 | 6,2 | 8,9 | 44,5 |
Short time liabilities | 3,7 | 5,2 | 8,1 | 57,3 |
Equity capital | 109,9 | 117,3 | 127,9 | 9 |
Operating profit (EBIT) | 5,4 | 5,6 | 8,1 | 42,8 |
Assets | 120,9 | 130,9 | 149,1 | 13,9 |
Net profit (loss) | 3,1 | 7,4 | 10,6 | 43,6 |
Cash | 23 | 27,3 | 22,6 | -17 |
Net income from sale | 66,3 | 74,8 | 98,3 | 31,5 |
Liabilities and provisions for liabilities | 11 | 13,6 | 21,2 | 55,6 |
Working assets | 119,1 | 128,8 | 146,5 | 13,7 |
Depreciation | 0,6 | 0,5 | 0,9 | 62,4 |
% | % | % | p.p. | |
Profitability of capital | 2,8 | 6,3 | 8,3 | 2 |
Equity capital to total assets | 90,9 | 89,6 | 85,8 | -3,8 |
Gross profit margin | 8,1 | 14,5 | 15,9 | 1,4 |
EBITDA Margin | 9 | 8,2 | 9,1 | 0,9 |
Days | Days | Days | Days | |
Short term commitment turnover cycle | 21 | 25 | 30 | 5 |
Financial statements
01-01-2023 - 31-12-2023
Auditor's opinion / report on the audit of the annual financial statements
Download pdf01-01-2023 - 31-12-2023
Activity report
Download pdf01-01-2023 - 31-12-2023
Annual financial report
Download xml01-01-2023 - 31-12-2023
Annual financial report
Download pdf01-01-2023 - 31-12-2023
Annual financial report
Download pdf01-01-2023 - 31-12-2023
Resolution on profit distribution or loss coverage
Download pdf01-01-2023 - 31-12-2023
Resolution or decision approving the annual financial statements
Download pdfShow more (4)
uses security reCAPTCHA
Opinions
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane
0/ 5.0
How do you rate this company?
Your opinion matters to us.
Companies registered in the same sector
Gama Sp. z o.o.
Ruda Śląska
PROMEDIQ A Sp. z o.o.
Gdynia
CYTOGEN-POLSKA
ŁÓDŹ
Med Lux
Janów Lubelski
APIOMEDYKA Zaopatrzenie Medyczne
Koszalin
Emprime sp. z o.o.
Sękocin Nowy
Miodla Poland sp. z o.o.
Pszczyna
HS Medical Poland
Tychy
Wamed-Lab sp. z o.o.
Warszawa